Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.61 |
| ▸ | DUT | P33316 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078688 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL9218570 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2762704 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15866629 | 0.91 | DUT (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21089328 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL10521044 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL8909630 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19861744 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL24782135 | 0.89 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21089723 | 0.89 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105498-B2 | Acylated uridine and cytidine and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20020035086-A1 | Acylated uridine and cytidine and uses thereof | PRO NEURON, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5583117-A | CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; DIABETES | PRO-NEURON, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| US-5455339-A | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035086-A1 | Acylated uridine and cytidine and uses thereof | UMPS, PDF, RNASE1 | SLC28A1 703/4885SLC28A2 567/4885SLC29A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.